A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2023-03-23
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal
aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone
Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced
breast cancer that have certain disease characteristics.